|
|
 |
|
Viewing report
|
|
|
|
Commercial And Pipeline Insight: ADHD - Immature Adult Market Continues To Offer Greatest Commercial Potential
Datamonitor, April 2008, Pages: 211
Introduction
The ADHD market is currently valued at $3.85 billion and is set to increase over the next 10 years at a CAGR of 1.2%. Despite the continuing dominance of stimulant drugs, the 2002 launch of Strattera, the first non-stimulant treatment for ADHD, and the 2006 launch of Daytrana have served to open up the market, giving patients and physicians a greater choice of treatment options.
Scope
Sales volume and value forecasts to 2017 of marketed brands, generics, and key late-stage pipeline drugs.
Analysis of patient potential, unmet needs and clinical trial design in the ADHD market.
Overview of key marketed brands and late stage pipeline drugs.
Identification of future market events that are expected to affect ADHD revenues.
Highlights
Estimated to be twice the size of the pediatric ADHD population, the highly prevalent, yet largely untapped, adult ADHD population continues to represent an attractive niche to target. The rising awareness of ADHD brought about by marketing campaigns for Adderall XR and Strattera has paved the way for the entry of additional adult ADHD drugs.
Due to a lack of innovation, none of the forecast drugs have the potential to match the commercial success experienced by currently marketed brands. Shires Intuniv (guanfacine) is expected to be positioned as a second-line treatment and will benefit from the companys established reputation in the market.
J&Js Concertas strong uptake is due to its first-to-market status as a once-daily ADHD treatment. Anticipated approval for use in adult patients, combined with Adderall XRs patent expiry will see Concerta becoming the market leader by 2017. However, owing to patent litigations, the timing of Concertas genericization remains uncertain.
Reasons to Purchase
Benchmark key late-stage pipeline ADHD drugs against current market leading brands.
Assess region-specific (US, Japan, 5EU) sales forecasts of key late-stage pipeline drugs and marketed brands.
Understand unmet needs and opportunities in the ADHD market based on key opinion leader comments.
Customers who bought this item also bought
Adult ADHD - Strattera Grows Up
Pipeline Insight: ADHD - Shire Driving Diversity in ADHD
Commercial Insight: ADHD - Strattera Reigns Supreme as Branded Stimulants Slump
Stakeholder Insight: ADHD - Prescriber Attention Still Held by Short Acting Stimulant Drugs
Adhd Market: Pestel Analysis and Scenario Based Forecasts
U.S. Attention Deficit Hyperactivity Disorder (ADHD) Markets
ADHD & Insomnia Treatments
Forecast Insight: Attention-Deficit Hyperactivity Disorder - Shire to stay on top despite drug safety fears and generic competition
US market size for attention deficit / hyperactivity disorder drugs by number of diagnosed and treated ADHD patients, number of prescriptions and ADHD drug sales in US dollars for 1999 forecast to 2004, with breakdown of dollar sales, Rx numbers and
US market size for attention deficit hyperactivity disorder drugs by number of diagnosed and treated ADHD patients, by number of ADHD prescriptions and by dollar value of ADHD pharmaceutical sales; breakout of percent market share, number of prescrip
Inhalers Clinical Trial Analysis
The ADD and ADHD Cure: The Natural Way to Treat Hyperactivity and Refocus Your Child
|
|
|
|
